Role of mu‐opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64‐6198 in rhesus monkeys

[1]  M. Banks,et al.  Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys , 2019, Behavioural pharmacology.

[2]  S. Schulz,et al.  Targeting multiple opioid receptors – improved analgesics with reduced side effects? , 2018, British journal of pharmacology.

[3]  K. Rice,et al.  Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[4]  K. Rice,et al.  Additive and subadditive antiallodynic interactions between &mgr;-opioid agonists and N-methyl D-aspartate antagonists in male rhesus monkeys , 2018, Behavioural pharmacology.

[5]  J. Ballantyne,et al.  Opioids for the Treatment of Chronic Pain: Mistakes Made, Lessons Learned, and Future Directions , 2017, Anesthesia and analgesia.

[6]  T. Haegerich,et al.  Using the CDC Guideline and Tools for Opioid Prescribing in Patients with Chronic Pain. , 2016, American family physician.

[7]  J. Siemian,et al.  Antinociceptive Interactions between the Imidazoline I2 Receptor Agonist 2-BFI and Opioids in Rats: Role of Efficacy at the μ-Opioid Receptor , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[8]  P. Saccone,et al.  Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[9]  M. Bruchas,et al.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems , 2016, Pharmacological Reviews.

[10]  C. Ghelardini,et al.  Nociceptin/orphanin FQ receptor and pain: Feasibility of the fourth opioid family member. , 2015, European journal of pharmacology.

[11]  D. Selley,et al.  Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats , 2015, Psychopharmacology.

[12]  C. France,et al.  Impact of Efficacy at the μ-Opioid Receptor on Antinociceptive Effects of Combinations of μ-Opioid Receptor Agonists and Cannabinoid Receptor Agonists , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[13]  G. Kellogg,et al.  Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists. , 2013, Bioorganic & medicinal chemistry.

[14]  D. Kyle,et al.  Roles of Mu Opioid Receptors and Nociceptin/Orphanin FQ Peptide Receptors in Buprenorphine-Induced Physiological Responses in Primates , 2012 .

[15]  K. Rice,et al.  Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics , 2010, Pharmacology Biochemistry and Behavior.

[16]  K. Rice,et al.  Antinociceptive Interactions between Mu-Opioid Receptor Agonists and the Serotonin Uptake Inhibitor Clomipramine in Rhesus Monkeys: Role of Mu Agonist Efficacy , 2010, Journal of Pharmacology and Experimental Therapeutics.

[17]  G. Calo’,et al.  Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112 , 2010, PAIN.

[18]  柯美全.  Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in primates , 2009 .

[19]  J. Woods,et al.  Behavioral Effects of a Synthetic Agonist Selective for Nociceptin/Orphanin FQ Peptide Receptors in Monkeys , 2009, Neuropsychopharmacology.

[20]  S. Salvadori,et al.  Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. , 2009, British journal of anaesthesia.

[21]  M. Ko,et al.  Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys. , 2009, The journal of pain : official journal of the American Pain Society.

[22]  D. Selley,et al.  Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. , 2009, Journal of medicinal chemistry.

[23]  K. Rice,et al.  Role of delta opioid efficacy as a determinant of mu/delta opioid interactions in rhesus monkeys. , 2009, European journal of pharmacology.

[24]  B. Kieffer,et al.  Effects of nociceptin/orphanin FQ receptor (NOP) agonist, Ro64-6198, on reactivity to acute pain in mice: comparison to morphine. , 2008, European journal of pharmacology.

[25]  D. Selley,et al.  Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at μ- and δ-Opioid Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.

[26]  K. Rice,et al.  Opioid Interactions in Rhesus Monkeys: Effects of δ + μ and δ + κ Agonists on Schedule-Controlled Responding and Thermal Nociception , 2003, Journal of Pharmacology and Experimental Therapeutics.

[27]  J. Kamei,et al.  TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys. , 2001, Japanese journal of pharmacology.

[28]  G. Adam,et al.  A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  N. Mello,et al.  Delta opioid antagonist effects of buprenorphine in rhesus monkeys. , 1999 .

[30]  D. Selley,et al.  Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus. , 1998, The Journal of pharmacology and experimental therapeutics.

[31]  D. Grandy,et al.  Bidirectional modulatory effect of orphanin FQ on morphine‐induced analgesia: antagonism in brain and potentiation in spinal cord of the rat , 1997, British journal of pharmacology.

[32]  J. Woods,et al.  Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. , 1995, The Journal of pharmacology and experimental therapeutics.

[33]  J. Woods,et al.  Opioid thermal antinociception in rhesus monkeys: receptor mechanisms and temperature dependency. , 1993, The Journal of pharmacology and experimental therapeutics.

[34]  D. A. Downs.  Interactions of acetylmethadol or methadone with other drugs in rhesus monkeys , 1979, Pharmacology Biochemistry and Behavior.

[35]  F. Carroll,et al.  Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats , 2017, Psychopharmacology.

[36]  Christopher A. Podlesnik,et al.  The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys , 2010, Psychopharmacology.

[37]  N. Mello,et al.  Antinociceptive effects of monoamine reuptake inhibitors administered alone or in combination with mu opioid agonists in rhesus monkeys , 1998, Psychopharmacology.